<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Chiesi USA, Inc.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/3M0BvyLRRkbh9NHm3EJHhw==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2024, Chiesi USA, Inc.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Wed, 09 Oct 2024 11:30:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/09/2960414/0/en/Chiesi-USA-Releases-2023-Sustainability-Report-and-Highlights-US-Community-Engagement-Strategy-Focus-Areas.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/09/2960414/0/en/Chiesi-USA-Releases-2023-Sustainability-Report-and-Highlights-US-Community-Engagement-Strategy-Focus-Areas.html</link>
      <category>1</category>
      <title>Chiesi USA Releases 2023 Sustainability Report and Highlights US Community Engagement Strategy Focus Areas</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Oct.  09, 2024  (GLOBE NEWSWIRE) -- <strong>Chiesi </strong>(key-A-zee), an international research-focused biopharmaceutical group, announced the release of its 2023<strong> Sustainability Report</strong>, available <a href="https://www.chiesi.com/en/about-us/annual-report-and-csr/" rel="nofollow" target="_blank" title="here">here</a>, which showed the company in 2023 has maintained its aggressive approach to delivering shared value for its stakeholders around the globe. Additionally, Chiesi announced today that its US community engagement focus areas in the US will address patients’ access to care, environmental impacts, food insecurity and STEM education as core enterprise level initiatives.</p>]]></description>
      <pubDate>Wed, 09 Oct 2024 11:30 GMT</pubDate>
      <dc:identifier>2960414</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Wed, 09 Oct 2024 11:30 GMT</dc:modified>
      <media:content
        medium="image"
        type="image/png"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/7fcdf986-72b4-40fd-9503-6ef759245646">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2024/10/09/2960414/0/en/Chiesi-USA-Releases-2023-Sustainability-Report-and-Highlights-US-Community-Engagement-Strategy-Focus-Areas.html">
    <img src="https://ml.globenewswire.com/Resource/Download/7fcdf986-72b4-40fd-9503-6ef759245646" width="600" align="left" border="0" alt="Chiesi 2023 Sustainability Report" title="Chiesi 2023 Sustainability Report" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <dc:subject>Research Analysis and Reports</dc:subject>
      <dc:keyword>Environmental</dc:keyword>
      <dc:keyword>Social</dc:keyword>
      <dc:keyword>Governance</dc:keyword>
      <dc:keyword>ESG</dc:keyword>
      <dc:keyword>Net-Zero</dc:keyword>
      <dc:keyword>EcoVadis</dc:keyword>
      <dc:keyword>STEM</dc:keyword>
      <dc:keyword>Volunteering</dc:keyword>
      <dc:keyword>Parentaly</dc:keyword>
      <dc:keyword>Employer</dc:keyword>
      <dc:keyword>Workplace</dc:keyword>
      <dc:keyword>Sustainability</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/16/2883338/0/en/Chiesi-to-Present-New-Data-Showcasing-Depth-of-Respiratory-Leadership-at-the-American-Thoracic-Society-2024-International-Conference.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/05/16/2883338/0/en/Chiesi-to-Present-New-Data-Showcasing-Depth-of-Respiratory-Leadership-at-the-American-Thoracic-Society-2024-International-Conference.html</link>
      <category>1</category>
      <title>Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference</title>
      <description><![CDATA[<p align="justify">CARY, N.C., May  16, 2024  (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the presentation of eight abstracts from Chiesi’s global respiratory research portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego from May 17-22, 2024. In addition, Chiesi will showcase its commitment to innovation through additional sponsorship opportunities aimed at addressing needs within the respiratory professional community through multiple avenues, including as the largest supporter of the annual ATS Research Program Benefit.</p>]]></description>
      <pubDate>Thu, 16 May 2024 12:00 GMT</pubDate>
      <dc:identifier>2883338</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Thu, 16 May 2024 12:01 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/04/15/2862720/0/en/Chiesi-USA-Appoints-Richard-Smith-as-Vice-President-and-Business-Unit-Leader-U-S-AIR.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/04/15/2862720/0/en/Chiesi-USA-Appoints-Richard-Smith-as-Vice-President-and-Business-Unit-Leader-U-S-AIR.html</link>
      <category>1</category>
      <title>Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR</title>
      <description><![CDATA[<p align="justify">CARY, N.C., April  15, 2024  (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR. Smith will report to Jon Zwinski, CEO and general manager of Chiesi USA.</p>]]></description>
      <pubDate>Mon, 15 Apr 2024 12:00 GMT</pubDate>
      <dc:identifier>2862720</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Mon, 15 Apr 2024 12:01 GMT</dc:modified>
      <dc:subject>Management Changes</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/08/08/2720737/0/en/Chiesi-Group-Mid-Year-Financial-Results-Demonstrate-Strong-Growth-for-2023.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/08/08/2720737/0/en/Chiesi-Group-Mid-Year-Financial-Results-Demonstrate-Strong-Growth-for-2023.html</link>
      <category>1</category>
      <title>Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Aug.  08, 2023  (GLOBE NEWSWIRE) -- <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA, Inc">Chiesi USA, Inc</a>. (key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Chiesi Group is continuing to experience major growth this year. The Group’s 2023 sales for the first half of the year are at €1,497 million, representing growth of 12% compared with 2022. EBITDA-on-sales ratio confirms to be above 30% in 2022. Chiesi USA, is the U.S. affiliate of Chiesi Farmaceutici, an international research-focused pharmaceutical group based in Parma, Italy with 31 affiliates worldwide.</p>]]></description>
      <pubDate>Tue, 08 Aug 2023 13:00 GMT</pubDate>
      <dc:identifier>2720737</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Tue, 08 Aug 2023 13:01 GMT</dc:modified>
      <dc:subject>Pre-Release Comments</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/07/20/2708249/0/en/Chiesi-USA-CEO-Appointed-to-ASHP-Foundation-Board-of-Directors.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/07/20/2708249/0/en/Chiesi-USA-CEO-Appointed-to-ASHP-Foundation-Board-of-Directors.html</link>
      <category>1</category>
      <title>Chiesi USA CEO Appointed to ASHP Foundation Board of Directors</title>
      <description><![CDATA[CEO Jon Zwinski to serve a two-year term on the Board of Directors starting in June 2023, deepening the partnership between Chiesi and ASHP <pre>CEO Jon Zwinski to serve a two-year term on the Board of Directors starting in June 2023, deepening the partnership between Chiesi and ASHP</pre>]]></description>
      <pubDate>Thu, 20 Jul 2023 13:00 GMT</pubDate>
      <dc:identifier>2708249</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Thu, 20 Jul 2023 13:00 GMT</dc:modified>
      <dc:subject>Directors and Officers</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/06/12/2686335/0/en/Chiesi-USA-Partners-with-Smith-Anderson-to-Host-1L-Excellence-in-Diversity-Fellow-this-Summer.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/06/12/2686335/0/en/Chiesi-USA-Partners-with-Smith-Anderson-to-Host-1L-Excellence-in-Diversity-Fellow-this-Summer.html</link>
      <category>1</category>
      <title>Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer</title>
      <description><![CDATA[Duke University School of Law student Cecilia Poston will work alongside Chiesi’s legal team to support her early career development and advance diversity, equity and inclusion in the profession <pre>Duke University School of Law student Cecilia Poston will work alongside Chiesi’s legal team to support her early career development and advance diversity, equity and inclusion in the profession</pre>]]></description>
      <pubDate>Mon, 12 Jun 2023 13:00 GMT</pubDate>
      <dc:identifier>2686335</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Mon, 12 Jun 2023 13:00 GMT</dc:modified>
      <dc:subject>Law &amp; Legal Issues</dc:subject>
      <dc:subject>Partnerships</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/04/11/2644473/0/en/2022-for-Chiesi-The-Group-s-international-growth-continues.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/04/11/2644473/0/en/2022-for-Chiesi-The-Group-s-international-growth-continues.html</link>
      <category>1</category>
      <title>2022 for Chiesi: The Group’s international growth continues</title>
      <description><![CDATA[<p align="justify">CARY, N.C., April  11, 2023  (GLOBE NEWSWIRE) -- The growth of Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma (Italy) and 31 Affiliates worldwide, continues.</p>]]></description>
      <pubDate>Tue, 11 Apr 2023 13:00 GMT</pubDate>
      <dc:identifier>2644473</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Tue, 11 Apr 2023 13:01 GMT</dc:modified>
      <dc:subject>Management statements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/03/28/2635729/0/en/Chiesi-USA-donates-more-than-830-000-to-local-communities-and-nonprofits-in-2022.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/03/28/2635729/0/en/Chiesi-USA-donates-more-than-830-000-to-local-communities-and-nonprofits-in-2022.html</link>
      <category>1</category>
      <title>Chiesi USA donates more than $830,000 to local communities and nonprofits in 2022</title>
      <description><![CDATA[<p align="justify">CARY, N.C., March  28, 2023  (GLOBE NEWSWIRE) -- <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA, Inc">Chiesi USA, Inc</a>. (key-A-zee), a Cary-based specialty pharmaceutical company, contributed more than $830,000 in 2022 through its Chiesi in the Community (CITC) corporate social responsibility (CSR) program. As an employee-led program, close to 200 Chiesi employees supported 65 unique charitable organizations with 769 hours of time or donations in 2022.</p>]]></description>
      <pubDate>Tue, 28 Mar 2023 13:00 GMT</pubDate>
      <dc:identifier>2635729</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Tue, 28 Mar 2023 13:01 GMT</dc:modified>
      <dc:subject>Financing Agreements</dc:subject>
      <dc:subject>Environmental, Social, and Governance Criteria</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/12/02/2566743/0/en/Chiesi-USA-Sponsors-ASHP-Advantage-Initiative-to-Support-Pharmacy-Technician-Recruitment-and-Retention.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/12/02/2566743/0/en/Chiesi-USA-Sponsors-ASHP-Advantage-Initiative-to-Support-Pharmacy-Technician-Recruitment-and-Retention.html</link>
      <category>1</category>
      <title>Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Dec.  02, 2022  (GLOBE NEWSWIRE) --  <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA">Chiesi USA</a> (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced its sponsorship of the ASHP (American Society of Health-System Pharmacists) Advantage initiative to support pharmacy technician recruitment and retention.</p>]]></description>
      <pubDate>Fri, 02 Dec 2022 14:00 GMT</pubDate>
      <dc:identifier>2566743</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Fri, 02 Dec 2022 14:00 GMT</dc:modified>
      <dc:subject>Product / Services Announcement</dc:subject>
      <dc:subject>Philanthropy</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/11/29/2564088/0/en/Chiesi-USA-Announces-Publication-of-Health-Economics-Analysis-of-Selective-Early-Rescue-Surfactant-Administration-vs-Standard-Surfactant-Administration-for-Premature-Infants-with-R.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/11/29/2564088/0/en/Chiesi-USA-Announces-Publication-of-Health-Economics-Analysis-of-Selective-Early-Rescue-Surfactant-Administration-vs-Standard-Surfactant-Administration-for-Premature-Infants-with-R.html</link>
      <category>1</category>
      <title>Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Nov.  29, 2022  (GLOBE NEWSWIRE) -- <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA">Chiesi USA</a> (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome (RDS). The paper appears in the online November/December 2022 edition of <em>The Journal of Pediatric Pharmacology and Therapeutics</em>.</p>]]></description>
      <pubDate>Tue, 29 Nov 2022 14:00 GMT</pubDate>
      <dc:identifier>2564088</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Tue, 29 Nov 2022 14:01 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/11/10/2553409/0/en/Chiesi-Group-joins-Biden-Administration-pledge-to-decarbonize-health-care-sector-make-facilities-resilient-to-climate-change.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/11/10/2553409/0/en/Chiesi-Group-joins-Biden-Administration-pledge-to-decarbonize-health-care-sector-make-facilities-resilient-to-climate-change.html</link>
      <category>1</category>
      <title>Chiesi Group joins Biden Administration pledge to decarbonize health care sector, make facilities resilient to climate change</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Nov.  10, 2022  (GLOBE NEWSWIRE) -- Chiesi Group, the international research-focused biopharmaceutical group, was celebrated by the U.S. Department of Health and Human Services (HHS) at the 2022 United Nations Climate Change Conference (COP27) on Nov. 10 for pledging ongoing action to decarbonize the healthcare sector and make healthcare facilities more resilient to the effects of climate change. Chiesi has formally committed to pursuing the Biden administration’s climate goal of reducing emissions by 50% by 2030 and achieving net zero emissions by 2050.</p>]]></description>
      <pubDate>Thu, 10 Nov 2022 14:28 GMT</pubDate>
      <dc:identifier>2553409</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Thu, 10 Nov 2022 14:28 GMT</dc:modified>
      <dc:subject>Environmental, Social, and Governance Criteria</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/10/17/2535563/0/en/Chiesi-USA-Chosen-as-One-of-Fortune-s-25-Best-Small-and-Medium-Workplaces-in-Biotechnology-and-Pharmaceuticals.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/10/17/2535563/0/en/Chiesi-USA-Chosen-as-One-of-Fortune-s-25-Best-Small-and-Medium-Workplaces-in-Biotechnology-and-Pharmaceuticals.html</link>
      <category>1</category>
      <title>Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Oct.  17, 2022  (GLOBE NEWSWIRE) -- <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA, Inc">Chiesi USA, Inc</a>. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has been ranked No. 15 among Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals.</p>]]></description>
      <pubDate>Mon, 17 Oct 2022 13:00 GMT</pubDate>
      <dc:identifier>2535563</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Mon, 17 Oct 2022 13:00 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Contests/Awards</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/10/03/2526908/0/en/Chiesi-USA-Partners-with-Durham-Bulls-to-Donate-15-000-to-Three-Triangle-Nonprofits.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/10/03/2526908/0/en/Chiesi-USA-Partners-with-Durham-Bulls-to-Donate-15-000-to-Three-Triangle-Nonprofits.html</link>
      <category>1</category>
      <title>Chiesi USA Partners with Durham Bulls to Donate $15,000 to Three Triangle Nonprofits</title>
      <description><![CDATA[Partnership is a home run as donations make a positive difference in the lives of North Carolinians <pre>Partnership is a home run as donations make a positive difference in the lives of North Carolinians</pre>]]></description>
      <pubDate>Mon, 03 Oct 2022 13:00 GMT</pubDate>
      <dc:identifier>2526908</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Mon, 03 Oct 2022 18:34 GMT</dc:modified>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/ae761dc0-8918-46f7-9f72-19f4c0a4c138">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2022/10/03/2526908/0/en/Chiesi-USA-Partners-with-Durham-Bulls-to-Donate-15-000-to-Three-Triangle-Nonprofits.html">
    <img src="https://ml.globenewswire.com/Resource/Download/ae761dc0-8918-46f7-9f72-19f4c0a4c138" width="600" align="left" border="0" alt="Chiesi Check Presentation Durham Bulls 2022" title="Jonathan Williams, Deputy General Counsel for Chiesi, presents the strikeout donations to representatives from Ronald McDonald House of Durham &amp; Wake and Activate Good. Children’s Flight of Hope not pictured." />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <dc:subject>Contests/Awards</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/09/22/2521264/0/en/Chiesi-is-Recertified-as-a-B-Corp-and-Sets-New-Tougher-Objectives-for-Action-by-2025.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/09/22/2521264/0/en/Chiesi-is-Recertified-as-a-B-Corp-and-Sets-New-Tougher-Objectives-for-Action-by-2025.html</link>
      <category>1</category>
      <title>Chiesi is Recertified as a B Corp and Sets New Tougher Objectives for Action by 2025</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Sept.  22, 2022  (GLOBE NEWSWIRE) -- The B Corp movement, established to help companies balance profit with purpose, is growing by the day. Today there are more than 5,700 companies part of the movement that decided to subject themselves to a rigorous social and environmental impact assessment and evaluation by a recognized and impartial third party that credits actions over words. In this sense, Chiesi renews its commitment towards a community of businesses that believe in pursuing a different kind of economy, one that is inclusive, equitable and regenerative.</p>]]></description>
      <pubDate>Thu, 22 Sep 2022 15:45 GMT</pubDate>
      <dc:identifier>2521264</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Thu, 22 Sep 2022 15:45 GMT</dc:modified>
      <dc:subject>Restructuring / Recapitalization</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/09/06/2510538/0/en/Chiesi-USA-Reports-Progress-in-ASHP-Foundation-s-Pharmacy-Leadership-Scholars-Program.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/09/06/2510538/0/en/Chiesi-USA-Reports-Progress-in-ASHP-Foundation-s-Pharmacy-Leadership-Scholars-Program.html</link>
      <category>1</category>
      <title>Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars Program</title>
      <description><![CDATA[<p align="justify">CARY, N.C., Sept.  06, 2022  (GLOBE NEWSWIRE) -- <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA">Chiesi USA</a> (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), sponsored the ASHP Foundation Pharmacy Leadership Scholars program in providing $50,000 worth of research grants. Through Chiesi and the ASHP Foundation’s partnership, announced in March of 2021, five early-stage pharmacist researchers were given $10,000 grants as part of the innovative program, which supports meaningful research that advances diversity, equity, inclusion (DE&amp;I) and access in healthcare.</p>]]></description>
      <pubDate>Tue, 06 Sep 2022 13:10 GMT</pubDate>
      <dc:identifier>2510538</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Tue, 06 Sep 2022 13:10 GMT</dc:modified>
      <dc:subject>Financing Agreements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/07/25/2485113/0/en/Chiesi-Group-joins-White-House-pledge-to-decarbonize-healthcare-sector.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/07/25/2485113/0/en/Chiesi-Group-joins-White-House-pledge-to-decarbonize-healthcare-sector.html</link>
      <category>1</category>
      <title>Chiesi Group joins White House pledge to decarbonize healthcare sector</title>
      <description><![CDATA[<p align="justify">CARY, N.C., July  25, 2022  (GLOBE NEWSWIRE) -- Chiesi, the international research-focused biopharmaceutical group, signed the U.S. Department of Health and Human Services (HHS) Health Care Sector Climate Pledge, committing to reduce greenhouse gas emissions 50% by 2030. The pledge was developed by The Office of Climate Change and Health Equity (OCCHE) in conjunction with the White House.</p>]]></description>
      <pubDate>Mon, 25 Jul 2022 13:00 GMT</pubDate>
      <dc:identifier>2485113</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Mon, 25 Jul 2022 13:00 GMT</dc:modified>
      <dc:subject>Government News</dc:subject>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/07/14/2479785/0/en/Chiesi-tracks-actions-taken-for-a-healthier-more-sustainable-future.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/07/14/2479785/0/en/Chiesi-tracks-actions-taken-for-a-healthier-more-sustainable-future.html</link>
      <category>1</category>
      <title>Chiesi tracks actions taken for a healthier, more sustainable future</title>
      <description><![CDATA[<p align="justify">CARY, N.C., July  14, 2022  (GLOBE NEWSWIRE) -- Chiesi, the international research-focused biopharmaceutical group, today released its Annual and Sustainability Report for 2021. The report focuses not only on results, but also on tracking the actions taken to conduct its business more sustainably and responsibly.</p>]]></description>
      <pubDate>Thu, 14 Jul 2022 13:00 GMT</pubDate>
      <dc:identifier>2479785</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Thu, 14 Jul 2022 13:01 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Environmental, Social, and Governance Criteria</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/06/01/2454378/0/en/Chiesi-USA-Announces-First-Analysis-from-the-CAMEO-Registry-Assessing-KENGREAL-cangrelor-Use-and-Transition-to-Oral-P2Y12-Inhibitors-in-Routine-Clinical-Practice.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/06/01/2454378/0/en/Chiesi-USA-Announces-First-Analysis-from-the-CAMEO-Registry-Assessing-KENGREAL-cangrelor-Use-and-Transition-to-Oral-P2Y12-Inhibitors-in-Routine-Clinical-Practice.html</link>
      <category>1</category>
      <title>Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice</title>
      <description><![CDATA[<p align="justify">CARY, N.C., June  01, 2022  (GLOBE NEWSWIRE) -- <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA">Chiesi USA</a> (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced its first full analysis publication from the CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry that evaluated KENGREAL® (cangrelor) use and transition to oral P2Y<sub><strong>12</strong></sub> inhibitors in routine clinical practice. These results of the ongoing registry are now published in the Journal of the American Heart Association and can be accessed <a href="https://www.ahajournals.org/doi/10.1161/JAHA.121.024513" rel="nofollow" target="_blank" title="here">here</a>.</p>]]></description>
      <pubDate>Wed, 01 Jun 2022 13:00 GMT</pubDate>
      <dc:identifier>2454378</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Wed, 01 Jun 2022 13:02 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/04/11/2420116/0/en/Chiesi-Group-Continues-to-Grow-In-2021.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/04/11/2420116/0/en/Chiesi-Group-Continues-to-Grow-In-2021.html</link>
      <category>1</category>
      <title>Chiesi Group Continues to Grow In 2021</title>
      <description><![CDATA[<p align="justify">CARY, N.C., April  11, 2022  (GLOBE NEWSWIRE) -- Growth continues apace at <a href="https://www.chiesiusa.com/" rel="nofollow" target="_blank" title="Chiesi USA">Chiesi USA</a>, (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group). The international research-focused pharmaceutical group is based in Parma, Italy with 30 affiliates worldwide.</p>]]></description>
      <pubDate>Mon, 11 Apr 2022 13:00 GMT</pubDate>
      <dc:identifier>2420116</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Mon, 11 Apr 2022 13:00 GMT</dc:modified>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/03/16/2404462/0/en/Chiesi-USA-donates-more-than-815-000-to-local-communities-and-nonprofits-in-2021.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/03/16/2404462/0/en/Chiesi-USA-donates-more-than-815-000-to-local-communities-and-nonprofits-in-2021.html</link>
      <category>1</category>
      <title>Chiesi USA donates more than $815,000 to local communities and nonprofits in 2021</title>
      <description><![CDATA[Chiesi in the Community, Chiesi’s CSR initiative, provides significant contributions to the Triangle community and patient-focused nonprofits <pre>Chiesi in the Community, Chiesi’s CSR initiative, provides significant contributions to the Triangle community and patient-focused nonprofits</pre>]]></description>
      <pubDate>Wed, 16 Mar 2022 13:00 GMT</pubDate>
      <dc:identifier>2404462</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Chiesi USA, Inc.</dc:contributor>
      <dc:modified>Wed, 16 Mar 2022 13:01 GMT</dc:modified>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
  </channel>
</rss>